Definitions
from Wiktionary, Creative Commons Attribution/Share-Alike License.
- noun A
humanized monoclonal antibody with potential applications inoncology and in the treatment ofinflammatory autoimmune disorders such aslupus .
Etymologies
from Wiktionary, Creative Commons Attribution/Share-Alike License
Support
Help support Wordnik (and make this page ad-free) by adopting the word epratuzumab.
Examples
-
Immunomedics has been pursuing development of a monoclonal antibody known as epratuzumab for blood-related cancers for a long time, with results that aren't particularly inspiring or differentiated from a host of similar drugs from competitors.
unknown title Adam Feuerstein 2009
-
That trial, conducted on 227 lupus patients, sets the stage for the two companies to plan their third phase of human tests on the drug, called epratuzumab and still years away from potential approval.
Jacksonville Business News - Local Jacksonville News | Jacksonville Business Journal 2009
-
The so-called treatment advantage of epratuzumab over placebo in was 25%.
-
Studies in 4 B-cell lymphoma cell lines and 4 acute lymphoblastic leukemia cell lines confirmed the potent in vitro activity of epratuzumab-SN-38 in the nanomolar range.
Immunomedics Develops New Antibody-Drug Conjugate for Hematologic Cancer Therapy - Yahoo! Finance 2010
-
The SN-38 conjugate of epratuzumab is one of several agents created by our ADC program.
Immunomedics Develops New Antibody-Drug Conjugate for Hematologic Cancer Therapy - Yahoo! Finance 2010
-
Additionally, in a subcutaneous lymphoma model in mice, median survival time (MST) for untreated animals was only 7 days, while the tumor-specific epratuzumab-SN-38 conjugate in combination with veltuzumab increased MST 10-fold to more than 77 days.
-
Additionally, in a subcutaneous lymphoma model in mice, median survival time (MST) for untreated animals was only 7 days, while the tumor-specific epratuzumab-SN-38 conjugate in combination with veltuzumab increased MST 10-fold to more than 77 days.
-
The potential therapeutic activity of epratuzumab-SN-38 is the combined effect of both the antibody and the drug.
Immunomedics Develops New Antibody-Drug Conjugate for Hematologic Cancer Therapy - Yahoo! Finance 2010
-
Additionally, in a subcutaneous lymphoma model in mice, median survival time (MST) for untreated animals was only 7 days, while the tumor-specific epratuzumab-SN-38 conjugate in combination with veltuzumab increased MST 10-fold to more than 77 days.
-
Additionally, in a subcutaneous lymphoma model in mice, median survival time (MST) for untreated animals was only 7 days, while the tumor-specific epratuzumab-SN-38 conjugate in combination with veltuzumab increased MST 10-fold to more than 77 days.
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.